ISC
  • #ISC23
  • Access Virtual Experience
  • Access ePosters
  • Privacy Policy
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Program
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Program
Resources
  • #ISC23
  • Access Virtual Experience
  • Access ePosters
  • Privacy Policy
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconYouTube iconPinterest iconLinkedIn icon
Feb 8th, 2023

Session to debate over therapeutic options for secondary stroke prevention in AF patients


Lee Birnbaum, MD
Lee Birnbaum, MD

Managing atrial fibrillation (AF) patients prompts a “lively” debate: Which is the better therapeutic option — anticoagulants or AF ablation?

That question is the foundation of Thursday’s session, “Controversies in Secondary Stroke Prevention in Patients With AF (Debate).”

Novel oral anticoagulant (NOAC) therapeutics are the standard of care. But sometimes AF ablation or left atrial appendage closure also make sense.

“I am looking forward to a lively discussion of the pros and cons of the various therapeutic options,” said co-moderator Lee Birnbaum, MD, professor of neurology, neurosurgery and radiology at the University of Texas Health San Antonio.

“Some physicians might opt to use a NOAC because they say it is the standard of care, but ablation and appendage closure clearly have a role in the treatment algorithm. One size does not fit all.”

There are several unanswered questions regarding the use of anticoagulants versus AF ablation, Dr. Birnbaum said. Newer evidence points to the success of AF ablation in reducing stroke risk, particularly when used early after diagnosis.

There’s also technological advances and improved safety of left atrial appendage occluder devices. Cardiologists are doing more ablation procedures as well, improving skill and precision.

In debating the challenge of treating patients with AF prior to and after a stroke, Dr. Birnbaum said the first step is making an accurate AF diagnosis, then assessing all aspects of the patient’s risk of recurrent stroke. The CHADS-VASc score assists in determining risk.

Anticoagulation is a well-established preventive treatment. However, breakthrough embolic strokes occur, and some patients are vulnerable to bleeding complications. In this instance, ablation may allow the patient to forgo lifelong anticoagulant medicine.

Physicians must also determine a patient’s threshold of AF and its correlation to recurrent risk. 

Ablation is particularly helpful for AF and rapid ventricle response, Dr. Birnbaum said. But AF can return even after ablation, suggesting the patient may continue to need lifelong monitoring.

“Cardiologists are doing more of these procedures every day,” Dr. Birnbaum said. “It is a promising option for patients who can’t be on anticoagulants or perhaps do not want to take blood thinners for their entire life. One’s cumulative risk from lifelong anticoagulation needs to be considered in this treatment algorithm. The HAS-BLED score was developed to assess bleeding risk in clinical practice.”

For patients who require or choose ablation, however, there’s minimal increased risk at the time of the procedure. This includes bleeding at the groin or experiencing AF. More serious complications, though rare, can occur as well. 

Interesting Stories
NeuroLogica brings you the next generation SmartMSU™
Sponsored by NeuroLogica
NeuroLogica brings you the next generation SmartMSU™
Venous outflow and parenchymal hemorrhage: A clogged drain problem?
Sponsored by American Heart Association/American Stroke Association
Venous outflow and parenchymal hemorrhage: A clogged drain problem?
ISC23 Welcome Guide
Sponsored by Microvention
ISC23 Welcome Guide
Telehealth after stroke care pilot randomized trial...
Sponsored by American Heart Association/American Stroke Association
Telehealth after stroke care pilot randomized trial...
More Content
Getty Images 861104740
Late-Breaking Science
Late-Breaking Science: BEST-II, CATIS-2, ANGEL-ASPECT, SELECT 2, ARAMIS, RESCUE BT2 and CMOSS
Feb 13th, 2023
audience listening to a presentation
Daily Coverage
Schedule of Main Events
Jan 24th, 2023
Home
Access live stream and on-demand sessions for #ISC23
Dec 26th, 2022
McDermott headshot
Home
Pre-Conference: Stroke in the Real World
Dec 26th, 2022
Bruce Ovbiagele headshot
Home
Pre-Conference: HEADS-UP
Dec 26th, 2022
Dusenbury headshot
Home
Pre-Conference: State-of-the-Science Stroke Nursing Symposium
Dec 26th, 2022
Stroke audience
Home
Late-Breaking Science for #ISC23
Dec 26th, 2022
Torch and flame logo
Home
Register now for #ISC23
Dec 26th, 2022